levoleucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   30 Trials   30 Trials   224 News 


«12345»
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial completion date, Trial primary completion date, Metastases:  BeTRI: Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer (clinicaltrials.gov) -  Apr 7, 2019   
    P2,  N=45, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Feb 2019 --> May 2019 Trial completion date: Sep 2018 --> May 2019 | Trial primary completion date: Sep 2018 --> May 2019
  • ||||||||||  Vectibix (panitumumab) / Amgen
    Trial completion date, Trial primary completion date:  PARADIGM: Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC (clinicaltrials.gov) -  Nov 14, 2018   
    P3,  N=823, Active, not recruiting, 
    Trial completion date: Sep 2018 --> May 2019 | Trial primary completion date: Sep 2018 --> May 2019 Trial completion date: May 2020 --> Mar 2020 | Trial primary completion date: May 2020 --> Mar 2020
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
    Trial completion, Combination therapy, Metastases:  Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer (clinicaltrials.gov) -  Aug 29, 2018   
    P2,  N=84, Completed, 
    Not yet recruiting --> Recruiting Active, not recruiting --> Completed
  • ||||||||||  Vectibix (panitumumab) / Amgen
    Trial completion date, Trial primary completion date:  PARADIGM: Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC (clinicaltrials.gov) -  Jul 23, 2018   
    P3,  N=823, Active, not recruiting, 
    Initiation date: May 2018 --> Sep 2018 | Trial primary completion date: Jul 2019 --> Oct 2019 Trial completion date: Feb 2020 --> May 2020 | Trial primary completion date: Feb 2020 --> May 2020
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer (clinicaltrials.gov) -  Jun 6, 2018   
    P2,  N=80, Active, not recruiting, 
    Phase classification: P3 --> P2 Trial completion date: May 2018 --> Sep 2018 | Trial primary completion date: May 2018 --> Sep 2018
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
    Trial primary completion date, Combination therapy, Metastases:  Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer (clinicaltrials.gov) -  Jan 23, 2018   
    P2,  N=80, Active, not recruiting, 
    N=60 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Dec 2017 --> Apr 2018
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
    Enrollment closed, Combination therapy, Metastases:  Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer (clinicaltrials.gov) -  Apr 6, 2017   
    P2,  N=80, Active, not recruiting, 
    Trial primary completion date: Sep 2018 --> Apr 2017 Recruiting --> Active, not recruiting
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
    Enrollment open, Combination therapy, Metastases:  Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer (clinicaltrials.gov) -  Apr 6, 2016   
    P2,  N=80, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting